APL, a manufacturer of extemporaneous medicines and a contract development and manufacturing organization (CDMO) in Sweden, has joined forces with CurifyLabs, a Finnish health tech company creating personalized medicine manufacturing solutions, to improve the administration of medicines to children and critically ill patients using novel 3D printing technology.
 
Compared with traditional pharmaceutical processes, 3D printing can produce more personalized dosages and dosage forms, with flexible shapes and structures. It also enables precise dosing, which helps reduce side effects.
 
APL uses a manufacturing method that produces at least 100 capsules per batch, but with 3D printing technology, precise doses can be created, reducing waste and promoting sustainability. This automated approach will also provide a better working environment for staff, with a lower risk of repetitive strain injuries and limited exposure to toxic substances.
 
Erik Haeffler, CEO at APL, said, “We are very impressed with CurifyLabs’ commitment to supporting us on our journey to address the urgent unmet needs of critically ill patients. 3D printing is an exciting technology that is well-suited to extemporaneous manufacturing. It will give us additional opportunities to fulfill our public policy assignment.”
 
Charlotta Topelius, CEO at CurifyLabs, added, “APL has demonstrated its strong capabilities in extemporaneous medicines with high quality and consistency, which will be critical to accelerating our development efforts together. We look forward to combining our strengths to create even greater value for patients needing personalized medicines.”
 
APL expects to provide fully compliant and validated 3D-printed extemporaneous medicines to the Swedish market by 2025, with the first 3D printers to be delivered in September 2024.